HUTCHMED (China) Limited
HCM · AIM · Health Care · mcap £1,764m · 215.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 29 Sep 26 | Submission of US NDA for ORPATHYS® plus TAGRISSO
AstraZeneca submits US NDA for ORPATHYS plus TAGRISSO combination in MET-driven EGFR-mutated lung cancer. |
+2.9% | |
| 28 Sep 26 | HUTCHMED Initiates Global Trial of HMPL-A830
HUTCHMED initiates global Phase I trial of HMPL-A830, a KRAS-EGFR antibody conjugate, with GSK licensed for development outside Greater China. |
−3.2% | |
| 24 Sep 26 | Data to be Presented at ESMO 2026
HUTCHMED to present data from Phase III studies of savolitinib and osimertinib combination at ESMO 2026. |
−3.2% | |
| 03 Sep 26 | HUTCHMED Licenses KRAS-EGFR-Antibody to GSK
HUTCHMED licenses KRAS-EGFR antibody therapy HMPL-A830 to GSK for worldwide rights excluding Greater China. |
+16.4% | |
| 01 Sep 26 | SANOVO trial demonstrated significant PFS benefit
SANOVO Phase III trial showed ORPATHYS plus TAGRISSO significantly improved progression-free survival in treatment-naïve MET-overexpressing EGFR-mutated lung cancer patients. |
−2.2% | |
| 28 Aug 26 | NMPA Approval for ATLED® (Fanregratinib) for ICC
NMPA grants conditional approval for ATLED (fanregratinib) for FGFR2-altered advanced intrahepatic cholangiocarcinoma in China. |
−0.8% | |
| 18 Aug 26 | Announcement pursuant to AIM Rule 17 Schedule 2(g)
Chairman's former company S.D. Sight entered insolvency proceedings in Israel; no impact on Group. |
−0.5% | |
| 17 Aug 26 | Orpathys+Tagrisso improved PFS & OS in EGFRm lung
SAFFRON Phase III trial shows ORPATHYS plus TAGRISSO improved progression-free and overall survival versus chemotherapy in EGFRm lung cancer with MET resistance. |
+2.7% | |
| 30 Jul 26 | Results | HUTCHMED Reports 2026 Interim Results
H1 2026 interim results show China product sales growth of over 40%, FRUZAQLA ex-US up 70%, net income $15.9m, cash $1.37bn. |
−3.5% |
| 02 Jul 26 | NMPA Approval for ORPATHYS
NMPA grants conditional approval for ORPATHYS for MET-amplified gastric cancer, third approved indication in China. |
+9.0% | |
| 30 Jun 26 | Results | HUTCHMED to Announce 2026 Half-Year Results
HUTCHMED to announce half-year results for six months ended 30 June 2026. |
+1.2% |
| 29 Jun 26 | Announcement on blocklisting six monthly return
Hong Kong, Shanghai, & Florham Park, NJ - Monday, June 29, 2026: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: |
+0.0% | |
| 25 Jun 26 | HUTCHMED Highlights Phase II Data at ESMO
Phase II pivotal data for fanregratinib in FGFR2-fusion intrahepatic cholangiocarcinoma presented at ESMO congress. |
−0.8% | |
| 12 Jun 26 | HUTCHMED Highlights Sovleplenib Phase III Data
Sovleplenib Phase III data in warm antibody autoimmune hemolytic anemia meets primary endpoint with 66% durable response rate. |
−2.5% | |
| 05 Jun 26 | Block Admission Application
Hong Kong, Shanghai & Florham Park, NJ - Friday, June 5, 2026: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; SEHK:13) today announces an application has been made to the London Stock Exchange p |
−6.4% | |
| 22 May 26 | HUTCHMED Highlights Data to be Presented at ASCO
HUTCHMED to present clinical data for savolitinib, fruquintinib and surufatinib at ASCO Annual Meeting. |
−1.5% | |
| 21 May 26 | NMPA approval for ELUNATE with TYVYT
NMPA approves ELUNATE with TYVYT for metastatic renal cell carcinoma, reducing disease progression risk by 63%. |
+4.9% | |
| 12 May 26 | Announcement on Results of Annual General Meeting
Annual General Meeting held on 12 May 2026; all resolutions passed by shareholders. |
+1.0% | |
| 30 Apr 26 | Routine | Total Voting Rights | |
| 29 Apr 26 | NDA Acceptance in China
NMPA accepts NDA for sovleplenib in warm antibody autoimmune hemolytic anemia with priority review and breakthrough designation. |
−1.7% | |
| 09 Apr 26 | Results | 2025 Annual Report and Notice of AGM
2025 Annual Report and Notice of Annual General Meeting |
−0.5% |
| 09 Apr 26 | Data to be Presented at AACR Annual Meeting 2026
HUTCHMED to present preclinical and clinical trial data at AACR meeting in April 2026. |
−0.5% | |
| 23 Mar 26 | HUTCHMED Initiates Phase III Trial of HMPL-760
HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory diffuse large B-cell lymphoma in China. |
+1.5% | |
| 16 Mar 26 | Routine | Vesting of awards under Long Term Incentive Plan | |
| 11 Mar 26 | Routine | Vesting of awards under Long Term Incentive Plan | |
| 09 Mar 26 | Update on Licensed Oncology Product in China
HUTCHMED withdrawing licensed oncology product TAZVERIK from China due to safety data from US partner Ipsen. |
−0.9% | |
| 06 Mar 26 | Board change | Directorate Change
Independent Non-executive Director Professor Mok retiring at AGM; board committee roles reassigned. |
+5.9% |
| 05 Mar 26 | Publication of Form 20-F
Hong Kong, Shanghai & Florham Park, NJ: Thursday, March 5, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today published the Form 20-F for the financial year ended December 31, 2025. |
−1.9% | |
| 05 Mar 26 | Results | 2025 Full Year Results and Business Updates
2025 full year results with $457m net income including $415.8m divestment gain; FRUZAQLA sales up 26%, China sales down; ATTC platform in clinical trials. |
−1.9% |
| 04 Mar 26 | HUTCHMED Initiates Global Trial of ATTC Candidate
HUTCHMED initiates Phase I/IIa trial of HMPL-A580, a PI3K/PIKK-EGFR antibody-drug conjugate for solid tumors. |
+1.4% | |
| 06 Feb 26 | Results | HUTCHMED to Announce 2025 Final Results
HUTCHMED to announce 2025 final results on March 5, 2026 with analyst webcasts. |
−1.8% |
| 14 Jan 26 | Publication of Phase III Results in The Lancet
Phase III SACHI trial results published in The Lancet showing savolitinib plus osimertinib combination met primary endpoint in advanced NSCLC. |
−5.0% | |
| 07 Jan 26 | Results | Positive Topline Results of Phase III Trial
Phase III trial of sovleplenib met primary endpoint for warm antibody autoimmune hemolytic anemia in China. |
+1.4% |
| 05 Jan 26 | Surufatinib + Camrelizumab PDAC Phase 3 initiation
Phase III initiation of surufatinib plus camrelizumab combination trial for treatment-naïve pancreatic cancer in China. |
−1.0% | |
| 31 Dec 25 | Routine | Total Voting Rights | |
| 30 Dec 25 | China NDA Acceptance-Savolitinib in Gastric Cancer
China accepts NDA with priority review for savolitinib in MET-amplified gastric cancer, supported by positive Phase II data. |
−0.3% | |
| 29 Dec 25 | NDA Acceptance in China for Fanregratinib
NDA accepted with priority review in China for fanregratinib in second-line intrahepatic cholangiocarcinoma. |
+1.3% | |
| 29 Dec 25 | Routine | Blocklisting Six Monthly Return | |
| 17 Dec 25 | HUTCHMED Initiates Development of ATTC Candidate
HUTCHMED initiates Phase I/IIa trial of HMPL-A251, first clinical candidate from next-generation ATTC platform, in HER2-expressing solid tumors. |
+1.0% | |
| 08 Dec 25 | Expanded NRDL Coverage + CIDL Inclusion in China
Four cancer drugs gain NRDL coverage or Commercial Insurance Drug List inclusion in China from January 2026. |
−1.9% | |
| 28 Nov 25 | Routine | Total Voting Rights | |
| 27 Nov 25 | HUTCHMED Highlights Data at ESMO and ASH
HUTCHMED to present clinical data from multiple drug studies at ESMO Asia Congress and ASH Annual Meeting. |
−1.1% | |
| 05 Nov 25 | Enrollment Complete in SAFFRON Global Phase III
SAFFRON Phase III trial of ORPATHYS and TAGRISSO combination for lung cancer completes enrollment of 338 patients. |
−2.4% | |
| 03 Nov 25 | Updates from R&D Event
HUTCHMED unveiled ATTC platform with lead candidate HMPL-A251 and reported progress in late-stage pipeline studies. |
+6.4% | |
| 23 Oct 25 | HUTCHMED Presents Data at AACR NCI EORTC
HUTCHMED presents preclinical data for HMPL-A251, a PI3K/PIKK-HER2 antibody-targeted therapy conjugate showing antitumor activity. |
+0.4% | |
| 21 Oct 25 | Routine | Vesting of awards under Long Term Incentive Plan | |
| 14 Oct 25 | Board change | Appointment of Independent Non-executive Director
Professor Tan Shao Weng, Daniel appointed as Independent Non-executive Director with effect from October 15, 2025. |
−1.7% |
| 13 Oct 25 | Data to be Presented at the 2025 ESMO Congress
FRUSICA-2 trial shows fruquintinib and sintilimab combination achieved 22.2 months median PFS in advanced renal cell carcinoma. |
−1.7% |
Company filings. Not investment advice.